TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15110902

Group type: EXPERIMENTAL
Intervention: 1.5 mg of slow-release indapamide SR
Number of subjects: 125

Group type: COMPARATOR
Intervention: 5 mg of amlodipine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 1.5 mg of slow-release indapamide SR + 4 mg of perindopril
Number of subjects: 125

Group type: COMPARATOR
Intervention: 5 mg of amlodipine + 4 mg of perindopril
Number of subjects: 125
Study: 11244764

Group type: EXPERIMENTAL
Intervention: dopamine 2 mcg.kg‐1.min‐1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: dobutamine 2 mcg.kg‐1.min‐1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 21
Study: 9547836

Group type: EXPERIMENTAL
Intervention: 4-step sequence
Number of subjects: 48

Group type: COMPARATOR
Intervention: 8-step sequence
Number of subjects: 48
Study: 8065152

Group type: EXPERIMENTAL
Intervention: Group A: 20 mg and 10 mg of mitomycin C IV on postoperative days 0 and 1, then tegafur at 600 mg/body daily PO from postoperative week 2 for 1 year.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Group B: 0.2 mg of mitomycin C per kg IV at 3, 6, 9, and 12 months after surgery.
Number of subjects: 336
Study: 3338348

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional intramuscular (IM) analgesia
Number of subjects: 62
Study: 29461422

Group type: EXPERIMENTAL
Intervention: Strength and power training program (high-load barbell movements)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bodyweight and rotational movement focused resistance training program (control)
Number of subjects: 12
Study: 30359693

Group type: EXPERIMENTAL
Intervention: Combined exercise (anaerobic and aerobic exercises) for 12 weeks, 3 times per week, intensity increased from 40% to 70% HRR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 20
Study: 26504102

Group type: COMPARATOR
Intervention: Risk Difference
Number of subjects: 531

Group type: COMPARATOR
Intervention: Relative Risk
Number of subjects: 531

Group type: COMPARATOR
Intervention: Ratio of Means
Number of subjects: 531

Group type: COMPARATOR
Intervention: Standardized Mean Difference
Number of subjects: 531

Group type: COMPARATOR
Intervention: Dichotomous Presentations (Relative Risk and Risk Difference)
Number of subjects: 531
Study: 24169022

Group type: EXPERIMENTAL
Intervention: Communication skills training related to depression (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No training (control group, n=19)
Number of subjects: 40
Study: 22446638

Group type: EXPERIMENTAL
Intervention: 3.75 μg MF59(®) adjuvanted vaccine
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59(®) adjuvanted vaccine
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: 15 μg non-adjuvanted vaccine
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: 3.75 μg MF59(®) adjuvanted vaccine (adults)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59(®) adjuvanted vaccine (elderly)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Booster administration after two priming doses
Number of subjects: 661
Study: 20033465

Group type: EXPERIMENTAL
Intervention: Two doses of MenACWY-CRM at 6 and 12 months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: One dose of MenACWY-CRM at 12 months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: One dose of MenC at 12 months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Two doses of MenACWY-CRM
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM given at 6 or 12 months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (two doses)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MenC (one dose)
Number of subjects: 175

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 175
Study: 19214262

Group type: EXPERIMENTAL
Intervention: Breakout sessions using actual legal cases
Number of subjects: 24
Study: 15870217

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Non-drinkers
Number of subjects: 1466
Study: 15221207

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg capsules daily)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo (one capsule daily)
Number of subjects: 378
Study: 10840355

Group type: EXPERIMENTAL
Intervention: Partial portacaval shunt (10-mm diameter interposition portacaval H-graft)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Direct side-to-side portacaval shunt
Number of subjects: 46
Study: 9100709

Group type: EXPERIMENTAL
Intervention: MHI score
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: IADL score
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: RD Scale
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: History of falls during the 3 months before hospitalization
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: BADL score
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Presence of incontinence
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: SA score
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Baseline CHP score
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Changes in MHI, IADL, and BADL score
Number of subjects: 1889
Study: 8173700

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 15
Study: 3456381

Group type: EXPERIMENTAL
Intervention: Videotaped dental fear-reduction program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videotaped placebo group
Number of subjects: 0
Study: 2455089

Group type: EXPERIMENTAL
Intervention: Pharmacological protection with coenzyme Q (5 mg/kg) and aprotinin (10,000 KIU/kg) administered intravenously every 12 hours post-surgery and a single dose intraoperatively.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group treated only with IABP.
Number of subjects: 50
Study: 30285125

Group type: EXPERIMENTAL
Intervention: β2-agonist terbutaline (0.2 to 0.4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29066444

Group type: EXPERIMENTAL
Intervention: Vitamin D3 200,000 IU followed by monthly 100,000 IU doses (n=71)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo monthly (n=79)
Number of subjects: 150
Study: 25946968

Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX GBG)
Number of subjects: 0
Study: 24377531

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG) 7.5 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mecobalamin (B12) 1500 μg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mecobalamin (B12)
Number of subjects: 60
Study: 21969500

Group type: EXPERIMENTAL
Intervention: Erlotinib maintenance therapy
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study: 19563428

Group type: EXPERIMENTAL
Intervention: Acute lower respiratory infection (ALRI) cases
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1208
Study: 16460239

Group type: EXPERIMENTAL
Intervention: SRP plus subgingival minocycline
Number of subjects: 26

Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 26
Study: 12382548

Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 13
Study: 10037386

Group type: EXPERIMENTAL
Intervention: High energy transurethral microwave therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 52
Study: 8625038

Group type: EXPERIMENTAL
Intervention: Methyl‐lomustine/5‐FU/Leucovorin (MFL) regimen (methyl‐lomustine 110 mg/m2 on Day 1 of each 8-week cycle, 5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Number of subjects: 319

Group type: COMPARATOR
Intervention: 5‐FU and Leucovorin (FL) regimen (5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Methyl‐lomustine/5‐FU/Leucovorin (MFL)
Number of subjects: 319

Group type: COMPARATOR
Intervention: 5‐FU and Leucovorin (FL)
Number of subjects: 319
Study: 2158151

Group type: EXPERIMENTAL
Intervention: Fragmin (2,500 U once per day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Heparin (5,000 IU b.i.d.)
Number of subjects: 250
Study: 7441728

Group type: EXPERIMENTAL
Intervention: High technical competence
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: High social competence
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low technical competence
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low social competence
Number of subjects: 192

Group type: COMPARATOR
Intervention: Female physicians
Number of subjects: 192

Group type: COMPARATOR
Intervention: Physicians with low physical attractiveness
Number of subjects: 192
Study: 29249041

Group type: EXPERIMENTAL
Intervention: 1:10 ketamine-propofol mixture (ketofol)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1:5 ketamine-propofol mixture (ketofol)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1:6.7 ketamine-propofol mixture (ketofol)
Number of subjects: 75
Study: 28438209

Group type: EXPERIMENTAL
Intervention: Non-episiotomy protocol (experimental group)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Selective episiotomy (control group)
Number of subjects: 241
Study: 25575197

Group type: EXPERIMENTAL
Intervention: Dentin Desensitizer with Optibond XTR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gluma with iBond
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MicroPrime B with Xeno IV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: iBond with no desensitizer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without desensitizer
Number of subjects: 120
Study: 24125620

Group type: EXPERIMENTAL
Intervention: Levocarnitine (3 g within 250 ml normal saline for intravenous infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional anti‐heart failure drugs
Number of subjects: 120
Study: 21360029

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 41781

Group type: EXPERIMENTAL
Intervention: Tailored interventions targeted toward men who have already undergone prostate cancer screening
Number of subjects: 41781

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening encounter
Number of subjects: 41781
Study: 18372471

Group type: EXPERIMENTAL
Intervention: CE MR angiography with 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 293
Study: 16520206

Group type: EXPERIMENTAL
Intervention: Acetabular cups with cement spacers made from polyethylene integrated into the cup
Number of subjects: 407

Group type: COMPARATOR
Intervention: Acetabular cups without cement spacers
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Acetabular cups with polyethylene spacers
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Cups placed at an angle of 45.0 degrees to 50.5 degrees
Number of subjects: 407
Study: 12897996

Group type: EXPERIMENTAL
Intervention: Opioid sedation during session 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisatracurium (muscle relaxant) during session 2
Number of subjects: 20
Study: 11131931

Group type: EXPERIMENTAL
Intervention: High frequency response alternatives/horizontal orientation (Condition A)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Medium frequency response alternatives/horizontal orientation (Condition B)
Number of subjects: 518

Group type: COMPARATOR
Intervention: High frequency response alternatives/vertical orientation (Condition C)
Number of subjects: 518
Study: 8781047

Group type: EXPERIMENTAL
Intervention: Elderly women (age > 65)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly men (age > 65)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly women (Grade II deformity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly men (Grade II deformity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 40 and over
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 40 and over (Grade II lesions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly women vs elderly men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-specific female-to-male ratio
Number of subjects: 0
Study: 1814768

Group type: EXPERIMENTAL
Intervention: Composite restorations (n = 64)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amalgam restorations (n = 55)
Number of subjects: 43
Study: 6849473

Group type: EXPERIMENTAL
Intervention: Health education intervention (exit interview)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health education intervention (home visit)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health education intervention (small group sessions)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 31595773

Group type: EXPERIMENTAL
Intervention: BBFC + PGA
Number of subjects: 188
Study: 30478855

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard breastfeeding education
Number of subjects: 0
Study: 29365058

Group type: EXPERIMENTAL
Intervention: 6-monthly 18FDG-PET/CT
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual monitoring alone
Number of subjects: 239
Study: 27436602

Group type: EXPERIMENTAL
Intervention: Sentinel CPS
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no Sentinel CPS)
Number of subjects: 65
Study: 24449597

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 50
Study: 24041270

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (405 mg/4 weeks, 300 mg/2 weeks, 150 mg/2 weeks)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Sub-therapeutic olanzapine long-acting injection (45 mg/4 weeks)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 1064
Study: 20797571

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease and Sagliker syndrome (SS)
Number of subjects: 13
Study: 17938978

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 2721

Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 2721
Study: 16021173

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 617

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 617
Study: 12509555

Group type: EXPERIMENTAL
Intervention: Increased carotid artery intimal-medial thickness (cIMT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Increased cIMT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cIMT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cIMT and LVMI
Number of subjects: 32
Study: 11005942

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 8883119

Group type: EXPERIMENTAL
Intervention: salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: calcium (500 mg/day)
Number of subjects: 112
Study: 1520160

Group type: EXPERIMENTAL
Intervention: Pre-test (subject-specific MCQ) before teaching demonstration on vascular disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-test (subject-specific MCQ) before teaching demonstration on traumatology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-test marks compared to pre-test marks
Number of subjects: 0
Study: 3917316

Group type: EXPERIMENTAL
Intervention: Natural progesterone given by mouth in increasing doses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31369392

Group type: EXPERIMENTAL
Intervention: High intensity intermittent training (HIIT), 3 days/week for 6 weeks
Number of subjects: 20
Study: 30001215

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency neurotomy of medial branches
Number of subjects: 71
Study: 27029823

Group type: COMPARATOR
Intervention: Venetoclax 50 mg (uncoated tablet)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Venetoclax film-coated 100 mg tablet after low-fat breakfast
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Venetoclax film-coated 100 mg tablet after high-fat breakfast
Number of subjects: 39

Group type: COMPARATOR
Intervention: Venetoclax under fasting conditions
Number of subjects: 39
Study: 24859237

Group type: EXPERIMENTAL
Intervention: Truth distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased proportion of truth distractor trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lie distractors
Number of subjects: 0
Study: 22260966

Group type: EXPERIMENTAL
Intervention: Alcohol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol and nicotine combined
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported anxiety after speech stressor with alcohol and nicotine
Number of subjects: 0
Study: 19797411

Group type: EXPERIMENTAL
Intervention: Night-only wear of upper and lower Hawley retainers for 1 year
Number of subjects: 67

Group type: COMPARATOR
Intervention: 6 months full-time followed by 6 months night-only wear of upper and lower Hawley retainers
Number of subjects: 67
Study: 18312743

Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CKD and HD patients
Number of subjects: 30
Study: 15562388

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 12218282

Group type: EXPERIMENTAL
Intervention: Formulation D
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study: 10589753

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2, i.v., over a 3-h period, escalated to 175 and 200 mg/m2; Cisplatin 80 mg/m2, i.v., day 1; Etoposide 50 mg/m2, i.v., day 1 and 100 mg/m2 p.o., days 2-3 for the first group, then 80 mg/m2, i.v., day 1 and 160 mg/m2, p.o., days 2-3 for subsequent groups
Number of subjects: 28
Study: 7917734

Group type: EXPERIMENTAL
Intervention: 1% prilocaine 20 ml (plain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% prilocaine 20 ml (alkalinized)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 2973665

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 1 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 1 mg at 6 am
Number of subjects: 10
Study: 31855785

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program, n=20
Number of subjects: 38

Group type: COMPARATOR
Intervention: Counseling, n=18
Number of subjects: 38
Study: 29866475

Group type: EXPERIMENTAL
Intervention: Once weekly carfilzomib (70 mg/m2)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Twice weekly carfilzomib (27 mg/m2)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Once weekly carfilzomib
Number of subjects: 478

Group type: COMPARATOR
Intervention: Twice weekly carfilzomib
Number of subjects: 478
Study: 28188155

Group type: EXPERIMENTAL
Intervention: Presentation framing the patient's absolute fracture risk as the chance of having or not having an event, with benefits from osteoporosis treatment in natural frequencies or numbers needed to treat.
Number of subjects: 200
Study: 24176024

Group type: EXPERIMENTAL
Intervention: Kiwifruit intervention (two green kiwifruit/d plus healthy diet)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control intervention (healthy diet alone)
Number of subjects: 85
Study: 22218119

Group type: EXPERIMENTAL
Intervention: Erythropoietin (PD‐Poietin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20380340

Group type: EXPERIMENTAL
Intervention: Phone-nurse-based system (group A)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nurse ambulatory system (group B)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 102
Study: 18293123

Group type: EXPERIMENTAL
Intervention: Motivational intervention (video-based)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Control (no motivational intervention)
Number of subjects: 1504
Study: 15737451

Group type: EXPERIMENTAL
Intervention: Single-axis total knee arthroplasty
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multi-axis total knee arthroplasty
Number of subjects: 16
Study: 12665996

Group type: EXPERIMENTAL
Intervention: Flow waveform method of triggering
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional flow triggering (2 l/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flow waveform method of cycling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional flow criterion of breath termination
Number of subjects: 12
Study: 10551702

Group type: COMPARATOR
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily
Number of subjects: 51
Study: 8828727

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3% eye drops twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fucidic acid 1% eye drops twice daily
Number of subjects: 45
Study: 1594263

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine, 0.3 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24
Study: 6510772

Group type: EXPERIMENTAL
Intervention: Dry monopolar - Cameron Miller (M)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Liquid monopolar - Storz (L)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Bipolar - Bicap ACMI (B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Heater probe - Seattle (H)
Number of subjects: 140